Hepatitis C Community
Hep C and Liver Transplant
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Hep C and Liver Transplant

Is it true that a person with Hep C and is in end stage Liver Disease is not eligible for a Liver Transplant?  I was talking with a friend of mine who had a Liver transplant a little over a year ago because of heavy drinking and presumably snorting Meth for a long time.  I told him well if my liver is so bad with fibrosis maybe I can get on the transplant list and he said people with Hep C are not eligible.  Thanks
Related Discussions
4 Comments Post a Comment
Blank
419309_tn?1326506891
It is NOT true that a person with hep c can't get a new liver.  A large majority of liver transplants are done BECAUSE of end-stage cirrhosis caused by uncured hep.  There may be other conditions that make someone ineligible, but as far as I know hep c is NOT one of them.
Blank
Avatar_m_tn
I thought so.  He is doing great by the way.  It's good to know there is always some hope.  thanks
Blank
96938_tn?1189803458
There are few things to keep in mind. If you have hcv and get a liver transplant, you will have hcv after and still have to treat the hcv.  Post-transplant treatment of hcv is very tricky.   Try to keep the original factory equipment, it matches the old chassis better.
Blank
Avatar_m_tn
Hepatogastroenterology. 2009 Jan-Feb;
  
Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y, Oya H, Yamamoto S, Kobayashi T, Watanabe T, Kokai H, Yamagiwa S, Hatakeyama K.

    Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Niigata, Japan. ***@****-u.ac.jp

    BACKGROUND/AIMS: Re-infection of hepatitis C virus (HCV) is very important for prognosis after liver transplantation of HCV cirrhosis. In the mechanism of re-infection of HCV, the peri-transplant immunity including the immunosuppression must be very important for getting the solution of prevention of its infection. (please rewrite this phrase). In this study, we investigated the influences of intraportal DST for HCV-reinfection after living related liver transplantation (LRLT). METHODOLOGY: The 12 patients, who underwent LRLT for the end-stage HCV liver cirrhosis from 1999 to 2007 in our hospital, were estimated about the influence of intraportal DST for re-infection of HCV. The nine persons of all patients had received the intraportal DST after LRLT. RESULTS: These nine patients could be steroid withdrawn within 2 months. The seven persons of all patients that received intraportal DST were treated with perioperative IFN therapy. Two patients had preoperative interferon-beta therapy. The one patient could obtain SVR. The other patient dropped out for the complications. The four patients had interferon-beta therapy in the acute hepatitis phase. Two patients had it in the chronic hepatitis phase. The one patient mentioned before, had preoperative IFN-beta and dropped out. HCV of the one patients without interferon therapy disappeared spontaneously from 3 months. The HCV disappeared in the 6 patients (66.7%) of all nine patients with intraportal DST after LRLT. The five of six patients were SVR. The patient who got preoperative IFN-beta revealed the macrochimerism of donor type CD56+T cell in the graft liver one month after LRLT. The immunological analysis about the patient, who got a spontaneous disappearance of HCV two months after LRLT, demonstrated that CD56+T cells strongly developed the both FasL and TRAIL expressions. CONCLUSION: In this study, the clinical and immunological findings suggested that intraportal DST might affect for the clearance of HCV by the both host immunity and IFN-ribavirin therapy.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
748543_tn?1371753642
Blank
TMJ/TMJ The Connection Between Teet...
Jan 27 by Hamidreza Nassery , DMD, FICOI, FAGDBlank
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
92903_tn?1309908311
Blank
GoofyDad
Marin County, CA
Avatar_f_tn
Blank
Livelife777
FL
1815939_tn?1377995399
Blank
pooh55811
446474_tn?1404424777
Blank
HectorSF
CA
Avatar_m_tn
Blank
can-do-man
IN
96938_tn?1189803458
Blank
FlGuy
South, FL